Who is sponsoring NCT03814850?

NCT03814850 is sponsored by Sebastian Koch.

What drugs are being tested in NCT03814850?

Interventions in NCT03814850: Standard Manual Aneroid Sphygmomanometer.

What condition does NCT03814850 study?

NCT03814850 studies Unruptured Cerebral Aneurysm.

Is NCT03814850 still recruiting?

NCT03814850 is currently withdrawn. Last updated 8 December 2023.

Last reviewed 2023-12-08 · How we verify

NCT03814850

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Remote Ischemic PreConditioning (RIPC)

Withdrawn NA Last updated 8 December 2023

What this trial tests

NA trial testing Standard Manual Aneroid Sphygmomanometer in Unruptured Cerebral Aneurysm. Withdrawn.

Timeline

1 December 2024

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Sebastian Koch
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	supportive care
Start date	1 December 2024
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	2 locations across United States

Drugs / interventions tested

Standard Manual Aneroid Sphygmomanometer

Conditions studied

Unruptured Cerebral Aneurysm — all drugs for Unruptured Cerebral Aneurysm →

Sponsor

Sebastian Koch

Who can join

18 and older, any sex, with Unruptured Cerebral Aneurysm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to learn about protecting the brain from low blood flow (ischemia) with limb preconditioning. From human studies the investigators know that the brain can be protected from dangerous low blood flow by reducing the blood flow to an arm or leg for just a short period of time. This is called limb preconditioning. The investigators are studying the safety and feasibility of preconditioning and their effect of protecting the brain from ischemia in two different groups. This is a Phase 2, randomized, double-blind, sham-controlled, design. Up to 50 male and female patients undergoing elective endovascular repair of unruptured brain aneurysm who are randomized to the remote ischemic preconditioned or sham group will be enrolled. This study consists of one 3-9 month study period for each patient plus up to 14 days for enrollment activities. Subjects are required to return between 3-9 months for end-of-study procedures.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Remote ischaemic conditioning for stroke: unanswered questions and future directions.
Baig S, Moyle B, Nair KPS, Redgrave J, et al · · 2021 · cited 15× · PMID 33903181 · DOI 10.1136/svn-2020-000722

Verify or expand the search:

Other recruiting trials for Unruptured Cerebral Aneurysm

Currently open trials in the same condition.

NCT06766422 — AI Models for Cerebral Aneurysms Segmentation, Detection and Stability Prediction · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03814850 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sebastian Koch
Last refreshed: 8 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03814850.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing